Stereotypic neutralizing V H antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals-Reference-Cited by-同舟云学术

Stereotypic neutralizing V H antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals

Published:2021-01-27 Issue:578 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kim Sang Il¹²^ORCID,Noh Jinsung³^ORCID,Kim Sujeong¹⁴^ORCID,Choi Younggeun¹^ORCID,Yoo Duck Kyun¹²⁴^ORCID,Lee Yonghee³^ORCID,Lee Hyunho³^ORCID,Jung Jongtak⁵,Kang Chang Kyung⁵,Song Kyoung-Ho⁵^ORCID,Choe Pyoeng Gyun⁵^ORCID,Kim Hong Bin⁵^ORCID,Kim Eu Suk⁵^ORCID,Kim Nam-Joong⁵^ORCID,Seong Moon-Woo⁶,Park Wan Beom⁵^ORCID,Oh Myoung-don⁵^ORCID,Kwon Sunghoon³⁷⁸⁹¹⁰^ORCID,Chung Junho¹⁴¹¹^ORCID

Affiliation:

1. Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.

2. Ischemic/Hypoxic Disease Institute, Seoul National University Medical Research Center, Seoul 03080, Republic of Korea.

3. Department of Electrical and Computer Engineering, Seoul National University, Seoul 08826, Republic of Korea.

4. Department of Biomedical Science, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.

5. Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.

6. Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.

7. Interdisciplinary Program in Bioengineering, Seoul National University, Seoul 08826, Republic of Korea.

8. BK21+ Creative Research Engineer Development for IT, Seoul National University, Seoul 08826, Republic of Korea.

9. Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.

10. Institutes of Entrepreneurial BioConvergence, Seoul National University, Seoul 08826, Republic of Korea.

11. Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.

Abstract

Stereotypic neutralizing antibody clonotypes specific for SARS-CoV-2 receptor binding domain in patients with COVID-19 and healthy individuals.

Funder

National Research Foundation of Korea

Ministry of Science and ICT, South Korea

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference52 articles.

1. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen

2. Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization

3. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures

4. The potential danger of suboptimal antibody responses in COVID-19

5. Viral-Induced Enhanced Disease Illness

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants;Immunity;2023-12

2. SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes;Cell Reports Medicine;2023-11

3. The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus;Cell Reports;2023-11

4. Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection;mBio;2023-10-31

5. Fast clonal family inference from large-scale B cell repertoire sequencing data;Cell Reports Methods;2023-10